Acceptance and Opinions of Intanza/IDflu Intradermal Influenza Vaccine in the Czech Republic and Turkey

Creative Commons License

Prymula R., USLUER G., Altinel S., Sichova R., Weber F.

ADVANCES IN THERAPY, cilt.29, sa.1, ss.41-52, 2012 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 29 Sayı: 1
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1007/s12325-011-0090-5
  • Dergi Adı: ADVANCES IN THERAPY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.41-52
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

IntanzaA (R)/IDfluA (R) (Sanofi Pasteur SA, Lyon, France), a split-virion, trivalent influenza vaccine delivered by intradermal injection with a microinjection system, became available in adults 18-59 years of age (9 mu g) and a parts per thousand yen60 years of age (15 mu g) as of the 2010/2011 northern hemisphere influenza season.